methyl 3-bromo-4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxylate | 188240-62-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: methyl 3-bromo-4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxylate
• 英文别名: methyl 3-bromo-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylate
• CAS: 188240-62-2
• 化学式: C₁₀H₁₁BrO₂S
• 分子量: 275.166
• InChiKey: VJSQBXFSPOTHED-UHFFFAOYSA-N

物化性质

• 熔点：
  85-86 °C
• 沸点：
  378.3±42.0 °C(Predicted)
• 密度：
  1.530±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-bromo-4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxylate 在 N-甲基吗啉 、 sodium hydroxide 、 2-氯-4,6-二甲氧基-1,3,5-三嗪 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 10.0h， 生成 dimethyl N-(3-bromo-4,5,6,7-tetrahydrobenzo[c]thienoyl)-L-glutamate
  参考文献：
  名称：

  Replacement of the 1‘,4‘-Phenylene Region in 5,10-Dideaza-5,6,7,8-tetrahydrofolic Acid (DDATHF) by 4,5,6,7-Tetrahydrobenzo[c]thiophene and 4,5,6,7-Tetrahydroisobenzofuran Nuclei

  摘要：

  Two new analogs of DDATHF, in which the 1',4'-phenylene unit is replaced by 4,5,6,7-tetrahydrobenzo[c]thiophene and 4,5,6,7-tetrahydroisobenzofuran nuclei, have been prepared and evaluated for in vitro cytotoxicity, GARFT inhibition, and FPGS affinity as potential antitumor agents.

  DOI：

  10.1021/jo9619903
• 作为产物：
  描述：

  4,5,6,7-四氢-2-苯并噻吩-1-羧酸 在 硫酸 、 溴 、 溶剂黄146 作用下， 反应 18.0h， 生成 methyl 3-bromo-4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxylate
  参考文献：
  名称：

  EP3466946

  摘要：

  公开号：

文献信息

• THIOPHENE, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL APPLICATION OF SAME
  申请人：CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD.

  公开号：EP3466946A1

  公开（公告）日：2019-04-10

  The present invention discloses a thiophene used as a uric acid transporter (URAT1) inhibitor and applicantion of the thiophene in preparing a pharmaceutical product for treating a disease related to abnormal uric acid levels, specifically in preparing a pharmaceutical product for treating hyperuricemia and gouty arthritis. The invention specifically relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了一种用作尿酸转运体（URAT1）抑制剂的噻吩，以及该噻吩在制备治疗与尿酸水平异常有关的疾病的药品中的应用，特别是在制备治疗高尿酸血症和痛风性关节炎的药品中的应用。本发明具体涉及由式（I）代表的化合物或其药学上可接受的盐。
• Thiophene, manufacturing method thereof, and pharmaceutical application of same
  申请人：CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD.

  公开号：US10829483B2

  公开（公告）日：2020-11-10

  The present invention discloses a thiophene used as a uric acid transporter (URAT1) inhibitor and application of the thiophene in preparing a pharmaceutical product for treating a disease related to abnormal uric acid levels, specifically in preparing a pharmaceutical product for treating hyperuricemia and gouty arthritis. The invention specifically relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了一种用作尿酸转运体（URAT1）抑制剂的噻吩，以及该噻吩在制备治疗与尿酸水平异常有关的疾病的药品中的应用，特别是在制备治疗高尿酸血症和痛风性关节炎的药品中的应用。本发明具体涉及一种由式（I）代表的化合物或其药学上可接受的盐。
• [EN] URICOSURIC AGENT, SYNTHETIC METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF<br/>[FR] AGENT URICOSURIQUE, SON PROCÉDÉ DE SYNTHÈSE ET SON APPLICATION PHARMACEUTIQUE<br/>[ZH] 一种尿酸促排剂及其合成方法和其在医药上的应用
  申请人：MEDSHINE DISCOVERY INC

  公开号：WO2021083182A1

  公开（公告）日：2021-05-06

  一类作为尿酸盐转运体(URAT1)抑制剂的尿酸促泄剂的化合物，及其在制备治疗尿酸水平异常病症药物中的应用。具体涉及式(I)所示化合物及其药学上可接受的盐。
• Thiophene, Manufacturing Method Thereof, And Pharmaceutical Application Of Same
  申请人：CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD.

  公开号：US20200140423A1

  公开（公告）日：2020-05-07

  The present invention discloses a thiophene used as a uric acid transporter (URAT1) inhibitor and application of the thiophene in preparing a pharmaceutical product for treating a disease related to abnormal uric acid levels, specifically in preparing a pharmaceutical product for treating hyperuricemia and gouty arthritis. The invention specifically relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.